Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RERG intronic transcript 1 (RERG-IT1) is annotated as a long non-coding RNA (lncRNA) associated with the RERG gene locus, which encodes a RAS-family GTPase known as RAS like estrogen regulated growth inhibitor[1][4]. This transcript is non-protein-coding and there is no evidence in major genomic or pharmacological databases that it encodes a therapeutic target, functions as a receptor, enzyme, transporter, or other canonical target class. There are also no known biological mechanisms, disease associations, biomarker uses, or drugs acting on this transcript according to current scientific resources[1][4][5]. The limited information suggests that RERG-IT1 is either a newly annotated or weakly characterized non-coding RNA, and it is not established as a target of therapeutic interest at this time. Note: If you are seeking information on the canonical RERG protein, there are significantly more data available on its tumor suppressor role as a protein-coding gene. For RERG-IT1, there is no evidence supporting therapeutic targeting, functional relevance, or disease association in current references[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RERG intronic transcript 1 (RERG-IT1).